Advertisement

Analytical and Bioanalytical Chemistry

, Volume 406, Issue 4, pp 1209–1219 | Cite as

Data-handling strategies for metabonomic studies: example of the UHPLC-ESI/ToF urinary signature of tetrahydrocannabinol in humans

  • Agneta Kiss
  • Claire Bordes
  • Corinne Buisson
  • Francoise Lasne
  • Pierre Lanteri
  • Cécile Cren-Olivé
Research Paper

Abstract

Metabonomics has become a very valuable tool and many research fields rely on results coming out from this combination of analytical techniques, chemometric strategies, and biological interpretation. Moreover, the matrices are more and more complex and the implications of the results are often of major importance. In this context, the need for pertinent validation strategies comes naturally. The choice of the appropriate chemometric method remains nevertheless a difficult task due to particularities such as: the number of measured variables, the complexity of the matrix and the purposes of the study. Consequently, this paper presents a detailed metabonomic study on human urine with a special emphasis on the importance of assessing the data's quality. It also describes, step by step, the statistical tools currently used and offers a critical view on some of their limits. In this work, 29 urine samples among which 15 samples obtained from tetrahydrocannabinol (delta-9-tetrahydrocannabinol)-consuming athletes, 5 samples provided by volunteers, and 9 samples obtained from athletes were submitted to untargeted analysis by means of ultra high-pressure liquid chromatography–electrospray ionization–time-of-flight mass spectrometry. Next, the quality of the obtained data was assessed and the results were compared to those found in databases. Then, unsupervised (principal component analysis (PCA)) and supervised (ANOVA/PCA, partial least-square–discriminant analysis (PLS-DA), orthogonal PLS-DA) univariate and multivariate statistical methods were applied.

Keywords

Metabonomics Doping LC-MS THC Chemometrics Validation 

Abbreviations

ANOVA

Analysis of variance

CE-MS

Capillary electrophoresis-mass spectrometry

CV

Coefficient of variation

GC-MS

Gaseous chromatography–mass spectrometry

LC-MS

Liquid chromatography–mass spectrometry

LC-ToF

Liquid chromatography–time-of-flight mass spectrometry

NMR

Nuclear magnetic resonance

OPLS

Orthogonal partial least-square analysis

PCA

Principal component analysis

PLS-DA

Partial least-square–discriminant analysis

QC

Quality control

THC

Tetrahydrocannabinol delta-9-tetrahydrocannabinol; (6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol

UHPLC-ESI/ToF

Ultra high-pressure liquid chromatography–electrospray ionization–time-of-flight mass spectrometry

Notes

Acknowledgments

The authors would like to acknowledge the contribution of the Rhone-Alpes Regional Council and the French anti-Doping Agency for the samples necessary to this work. We would also like to thank Aurélie Fildier for her technical help for the high resolution mass spectrometry.

Supplementary material

216_2013_7199_MOESM1_ESM.pdf (168 kb)
ESM 1 (PDF 167 kb)

References

  1. 1.
    Robertson DG, Watkins PB, Reily MD (2011) Metabolomics in toxicology: preclinical and clinical applications. Toxicol Sci 120:S146–S170CrossRefGoogle Scholar
  2. 2.
    Robertson DG, Reily MD, Baker JD (2007) Metabonomics in pharmaceutical discovery and development. J Proteome Res 6:526–539CrossRefGoogle Scholar
  3. 3.
    Dieterle F, Marrer E (2008) New technologies around biomarkers and their interplay with drug development. Anal Bioanal Chem 390:141–154CrossRefGoogle Scholar
  4. 4.
    Bao YQ, Zhao T, Wang XY, Qiu YP, Su MM et al (2009) Metabonomic variations in the drug-treated type 2 diabetes mellitus patients and healthy volunteers. J Proteome Res 8:1623–1630CrossRefGoogle Scholar
  5. 5.
    Wagner S, Scholz K, Donegan M, Burton L, Wingate J et al (2006) Metabonomics and biomarker discovery: LC-MS metabolic profiling and constant neutral loss scanning combined with multivariate data analysis for mercapturic acid analysis. Anal Chem 78:1296–1305CrossRefGoogle Scholar
  6. 6.
    Koulman A, Lane GA, Harrison SJ, Volmer DA (2009) From differentiating metabolites to biomarkers. Anal Bioanal Chem 394:663–670CrossRefGoogle Scholar
  7. 7.
    Ahmed S, Santosh W, Kumar S, Christlet HTT (2009) Metabolic profiling of Parkinson's disease: evidence of biomarker from gene expression analysis and rapid neural network detection. J Biomed Sci 16Google Scholar
  8. 8.
    Zhang AH, Sun H, Wang XJ (2012) Serum metabolomics as a novel diagnostic approach for disease: a systematic review. Anal Bioanal Chem 404:1239–1245CrossRefGoogle Scholar
  9. 9.
    Yap IKS, Brown IJ, Chan Q, Wijeyesekera A, Garcia-Perez I et al (2010) Metabolome-wide association study identifies multiple biomarkers that discriminate north and south Chinese populations at differing risks of cardiovascular disease INTERMAP Study. J Proteome R 9:6647–6654CrossRefGoogle Scholar
  10. 10.
    Wang XJ, Lv HT, Zhang GM, Sun WJ, Zhou DX et al (2008) Development and validation of a ultra performance LC-ESI/MS method for analysis of metabolic phenotypes of healthy men in day and night urine samples. J Sep Sci 31:2994–3001CrossRefGoogle Scholar
  11. 11.
    Xu EY, Schaefer WH, Xu QW (2009) Metabolomics in pharmaceutical research and development: metabolites, mechanisms and pathways. Curr Opin Drug Discov Dev 12:40–52Google Scholar
  12. 12.
    Lindon JC, Holmes E, Nicholson JK (2006) Metabonomics techniques and applications to pharmaceutical research and development. Pharm Res 23:1075–1088CrossRefGoogle Scholar
  13. 13.
    Nordstrom A, Lewensohn R (2010) Metabolomics: moving to the clinic. J Neuroimmune Pharm 5:4–17CrossRefGoogle Scholar
  14. 14.
    Guy PA, Tavazzi I, Bruce SJ, Ramadan Z, Kochhar S (2008) Global metabolic profiling analysis on human urine by UPLC-ToFMS: Issues and method validation in nutritional metabolomics. J Chromatogr B-Analytical Tech Biomed Life Sci 871:253–260CrossRefGoogle Scholar
  15. 15.
    Kaplan KA, Chiu VM, Lukus PA, Zhang X, Siems WF et al (2013) Neuronal metabolomics by ion mobility mass spectrometry: cocaine effects on glucose and selected biogenic amine metabolites in the frontal cortex, striatum, and thalamus of the rat. Anal Bioanal Chem 405:1959–1968CrossRefGoogle Scholar
  16. 16.
    Courant F, Pinel G, Bichon E, Monteau F, Antignac JP et al (2009) Development of a metabolomic approach based on liquid chromatography-high resolution mass spectrometry to screen for clenbuterol abuse in calves. Analyst 134:1637–1646CrossRefGoogle Scholar
  17. 17.
    Werner E, Heilier JF, Ducruix C, Ezan E, Junot C et al (2008) Mass spectrometry for the identification of the discriminating signals from metabolomics: current status and future trends. J Chromatogr B-Analytical Tech Biomed Life Sci 871:143–163CrossRefGoogle Scholar
  18. 18.
    Pasikanti KK, Ho PC, Chan ECY (2008) Gas chromatography/mass spectrometry in metabolic profiling of biological fluids. J Chromatogr B-Analytical Tech Biomed Life Sci 871:202–211CrossRefGoogle Scholar
  19. 19.
    Leon C, Rodriguez-Meizoso I, Lucio M, Garcia-Canas V, Ibanez E et al (2009) Metabolomics of transgenic maize combining Fourier transform-ion cyclotron resonance-mass spectrometry, capillary electrophoresis-mass spectrometry and pressurized liquid extraction. J Chromatogr A 1216:7314–7323CrossRefGoogle Scholar
  20. 20.
    Lu X, Zhao XJ, Bai CM, Zhao CX, Lu G et al (2008) LC-MS-based metabonomics analysis. J Chromatogr B-Analytical Tech Biomed Life Sci 866:64–76CrossRefGoogle Scholar
  21. 21.
    Hodavance MS, Ralston SL, Pelczer I (2007) Beyond blood sugar: the potential of NMR-based metabonomics for type 2 human diabetes, and the horse as a possible model. Anal Bioanal Chem 387:533–537CrossRefGoogle Scholar
  22. 22.
    Dettmer K, Aronov PA, Hammock BD (2007) Mass spectrometry-based metabolomics. Mass Spectrom Rev 26:51–78CrossRefGoogle Scholar
  23. 23.
    Lenz EM, Wilson ID (2007) Analytical strategies in metabonomics. J Proteome Res 6:443–458CrossRefGoogle Scholar
  24. 24.
    Plumb RS, Rainville P, Smith BW, Johnson KA, Castro-Perez J et al (2006) Generation of ultrahigh peak capacity LC separations via elevated temperatures and high linear mobile-phase velocities. Anal Chem 78:7278–7283CrossRefGoogle Scholar
  25. 25.
    Grata E, Boccard J, Guillarme D, Glauser G, Carrupt PA et al (2008) UPLC-ToF-MS for plant metabolomics: a sequential approach for wound marker analysis in Arabidopsis thaliana. J Chromatogr B-Analytical Tech Biomed Life Sci 871:261–270CrossRefGoogle Scholar
  26. 26.
    Kim KB, Chung MW, Um SY, Oh JS, Kim SH et al (2008) Metabolomics and biomarker discovery: NMR spectral data of urine and hepatotoxicity by carbon tetrachloride, acetaminophen, and d-galactosamine in rats. Metabolomics 4:377–392CrossRefGoogle Scholar
  27. 27.
    Zhao LC, Liu X, Xie LY, Gao HC, Lin DH (2010) 1H NMR-based metabonomic analysis of metabolic changes in streptozotocin-induced diabetic rats. Anal Sci 26:1277–1282CrossRefGoogle Scholar
  28. 28.
    Jahns GL, Kent MN, Burgoon LD, DelRaso N, Zacharewski TR et al (2009) Development of analytical methods for NMR spectra and application to a C-13 toxicology study. Metabolomics 5:253–262CrossRefGoogle Scholar
  29. 29.
    Stenlund H, Gorzsas A, Persson P, Sundberg B, Trygg J (2008) Orthogonal projections to latent structures discriminant analysis modeling on in situ FT-IR spectral imaging of liver tissue for identifying sources of variability. Anal Chem 80:6898–6906CrossRefGoogle Scholar
  30. 30.
    Miyagi A, Takahashi H, Takahara K, Hirabayashi T, Nishimura Y et al (2010) Principal component and hierarchical clustering analysis of metabolites in destructive weeds; polygonaceous plants. Metabolomics 6:146–155CrossRefGoogle Scholar
  31. 31.
    Viant MR, Ludwig C, Rhodes S, Guenther UL, Allaway D (2007) Validation of a urine metabolome fingerprint in dog for phenotypic classification. Metabolomics 3:453–463CrossRefGoogle Scholar
  32. 32.
    Li XY, Legido-Quigley C (2008) Advances in separation science applied to metabonomics. Electrophoresis 29:3724–3736CrossRefGoogle Scholar
  33. 33.
    Lauridsen M, Hansen SH, Jaroszewski JW, Cornett C (2007) Human urine as test material in H-1 NMR-based metabonomics: recommendations for sample preparation and storage. Anal Chem 79:1181–1186CrossRefGoogle Scholar
  34. 34.
    Fonville JM, Richards SE, Barton RH, Boulange CL, Ebbels TMD et al (2010) The evolution of partial least squares models and related chemometric approaches in metabonomics and metabolic phenotyping. J Chemom 24:636–649CrossRefGoogle Scholar
  35. 35.
    Wagner S, Scholz K, Sieber M, Kellert M, Voelkel W (2007) Tools in metabonomics: an integrated validation approach for LC-MS metabolic profiling of mercapturic acids in human urine. Anal Chem 79:2918–2926CrossRefGoogle Scholar
  36. 36.
    Sumner LW, Amberg A, Barrett D, Beale MH, Beger R et al (2007) Proposed minimum reporting standards for chemical analysis. Metabolomics 3:211–221CrossRefGoogle Scholar
  37. 37.
    Beckonert O, Bollard ME, Ebbels TMD, Keun HC, Antti H et al (2003) NMR-based metabonomic toxicity classification: hierarchical cluster analysis and k-nearest-neighbour approaches. Anal Chim Acta 490:3–15CrossRefGoogle Scholar
  38. 38.
    Ramadan Z, Jacobs D, Grigorov M, Kochhar S (2006) Metabolic profiling using principal component analysis, discriminant partial least squares, and genetic algorithms. Talanta 68:1683–1691CrossRefGoogle Scholar
  39. 39.
    Gika HG, Theodoridis GA, Wilson ID (2008) Liquid chromatography and ultra-performance liquid chromatography-mass spectrometry fingerprinting of human urine—sample stability under different handling and storage conditions for metabonomics studies. J Chromatogr A 1189:314–322CrossRefGoogle Scholar
  40. 40.
    Gika HG, Theodoridis GA, Wingate JE, Wilson ID (2007) Within-day reproducibility of an HPLC-MS-Based method for metabonomic analysis: application to human urine. J Proteome Res 6:3291–3303CrossRefGoogle Scholar
  41. 41.
    Sangster T, Major H, Plumb R, Wilson AJ, Wilson ID (2006) A pragmatic and readily implemented quality control strategy for HPLC-MS and GC-MS-based metabonomic analysis. Analyst 131:1075–1078CrossRefGoogle Scholar
  42. 42.
    Craig A, Cloareo O, Holmes E, Nicholson JK, Lindon JC (2006) Scaling and normalization effects in NMR spectroscopic metabonomic data sets. Anal Chem 78:2262–2267CrossRefGoogle Scholar
  43. 43.
    van den Berg RA, Hoefsloot HCJ, Westerhuis JA, Smilde AK, van der Werf MJ (2006) Centering, scaling, and transformations: improving the biological information content of metabolomics data. BMC Genomics 7Google Scholar
  44. 44.
    Eriksson L, Antti H, Gottfries J, Holmes E, Johansson E et al (2004) Using chemometrics for navigating in the large data sets of genomics, proteomics, and metabonomics (gpm). Anal Bioanal Chem 380:419–429CrossRefGoogle Scholar
  45. 45.
    Trygg J, Wold S (2002) Orthogonal projections to latent structures (O-PLS). J Chemom 16:119–128CrossRefGoogle Scholar
  46. 46.
    Hedenstrom M, Wiklund S, Sundberg B, Edlund U (2008) Visualization and interpretation of OPLS models based on 2D NMR data. Chemom Intell Lab Syst 92:110–117CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Agneta Kiss
    • 1
  • Claire Bordes
    • 2
  • Corinne Buisson
    • 3
  • Francoise Lasne
    • 3
  • Pierre Lanteri
    • 2
  • Cécile Cren-Olivé
    • 1
  1. 1.Institut des Sciences AnalytiquesUMR 5280 CNRS, Equipe TRACESVilleurbanneFrance
  2. 2.Institut des Sciences AnalytiquesUMR 5280 CNRS, Equipe CHEMOVilleurbanneFrance
  3. 3.Département des AnalysesAgence Française de Lutte contre le DopageChâtenay-MalabryFrance

Personalised recommendations